Iqvia price target lowered to $260 from $266 at Baird

Baird analyst Eric Coldwell lowered the firm’s price target on Iqvia to $260 from $266 and keeps an Outperform rating on the shares. The analyst said he reduced adjusted EPS slightly and to roughly align with the Street into the print. Valuation is slightly above clinical CRO peer closest in size, though not stretched in absolute terms.